No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Shenzhen Hepalink Pharmaceutical Group Co., Ltd., founded in 1998 and headquartered in Shenzhen, People's Republic of China, operates as an international pharmaceutical company. It is involved in the development, production, and distribution of a wide array of pharmaceutical goods, serving markets in Hong Kong, the United States, Europe, Mainland China, and other global regions. The company's operations are structured across four primary divisions. One key area is Finished Dose Pharmaceutical Products, prominently featuring enoxaparin sodium injection. Another significant segment focuses on Active Pharmaceutical Ingredients (API), supplying essential components like heparin sodium API, enoxaparin sodium API, and other specialized products such as pancreatin API. Hepalink also provides comprehensive services through its Contract Development and Manufacturing Organization (CDMO) arm, which encompasses research and development, manufacturing, quality assurance, and program management. Within its CDMO capabilities, the company is actively involved in creating advanced biopharmaceutical products, including recombinant pharmaceuticals, critical non-viral vectors, gene therapy intermediates, and naturally derived pharmaceutical substances. Beyond its core pharmaceutical activities, Hepalink diversifies its business interests through property management, investment management and advisory services, biopharmaceutical technology development and consulting, and equity and venture capital investments. The company also conducts research, development, and production of biopharmaceuticals, trades medical and biopharmaceutical products, and offers various pharmaceutical-related services. The company officially changed its name from Shenzhen Hepalink Pharmaceutical Co., Ltd. to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in February 2017.
www.hepalink.comNo one on the platform currently holds 9989.HK.
No tracked institution reports a position in 9989.HK as of their last filing.
No one on the platform has traded 9989.HK yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 4.2% | — | — | — | ||
| Rev. Growth % | 3.8% | 0.5% | ||||
| Profit Margin % | 6.4% | 3.6% | 9.6% | |||
| Free Cash Flow Margin % | 29.1% | 9.8% | -0.2% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $5.1B | -8.4% | $0.42 | $0.42–$0.42 | — | 1 |
| 2027 | $5.5B | +7.4% | $0.45 | $0.45–$0.45 | — | 1 |
| 2028 | $5.9B | +7.4% | $0.50 | $0.50–$0.50 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 6 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-28 | $0.09 | $0.07 | -23.6% |
| 2026-04-29 | $0.13 | $0.15 | +16.1% |
| 2026-03-29 | $-0.17 | $-0.16 | +4.9% |
| 2025-10-30 | $0.10 | $0.10 | -0.3% |
| 2025-08-29 | $0.02 | $0.20 | +821.7% |
| 2025-04-24 | $0.10 | $0.11 | +19.0% |
| 2025-03-26 | $-0.12 | $-0.10 | +17.7% |
| 2024-10-30 | $0.08 | $0.09 | +13.0% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 9989.HKShenzhen Hepalink Pharmaceutical Group Co., Ltd. | $3.76 | -9.51% | $12.7B | — |
| 0013.HKHUTCHMED (China) Limited | $21.54 | -1.19% | $18.7B | — |
| 0460.HKSihuan Pharmaceutical Holdings Group Ltd. | $0.72 | -0.69% | $6.5B | — |
| 0570.HKChina Traditional Chinese Medicine Holdings Co. Limited | $1.22 | -2.79% | $6.1B | — |
| 0719.HKShandong Xinhua Pharmaceutical Company Limited |
| $5.55 |
| +2.21% |
| $8.4B |
| — |
| 1681.HKConsun Pharmaceutical Group Limited | $13.31 | +1.06% | $11.2B | — |
| 1952.HKEverest Medicines Limited | $27.58 | +4.71% | $9.7B | — |
Source: Financial Modeling Prep · peers by sector/industry